Discover open access scientific publications

Search, annotate, share and cite publications

Publications by Jon E. Arnason

High Durable CR Rates and Preliminary Safety Profile for JCAR017 in R/R Aggressive B-NHL (TRANSCEND NHL 001 Study): A Defined Composition CD19-Directed CAR T Cell Product With Potential for Outpatient Administration

Biology of Blood and Marrow Transplantation

Transplantation

Hematology

2018

English

Related publications

Safety and Preliminary Efficacy in Patients With Relapsed/Refractory Mantle Cell Lymphoma Receiving Lisocabtagene Maraleucel in Transcend NHL 001

Hematological Oncology

English

A Phase I Trial of 19-28z Car-T Cells Post-High Dose Therapy and Autologous Transplantation (Hdt-Asct) for Relapsed and Refractory (R/R) B-Cell Non-Hodgkin Lymphoma (B-Nhl)

Hematological Oncology

English

Novel BAFF-R CAR T-Cell Therapy for CD19 Antigen-Loss Relapsed B Cell Tumors

Hematological Oncology

English

Phase Ib Study of Cc-122 in Combination With Obinutuzumab (Ga101): Relapsed or Refractory (R/R) Patients With B-Cell Non-Hodgkin Lymphomas (Nhl)

Hematological Oncology

English

VENETOCLAX (VEN), BENDAMUSTINE (B) AND RITUXIMAB (R) IN PATIENTS (PTS) WITH RELAPSED OR REFRACTORY (R/R) NON-HODGKIN LYMPHOMA (NHL): FINAL RESULTS OF a PHASE I STUDY

Hematological Oncology

English

High Rate of Durable Complete Remission in Follicular Lymphoma After Cd19 Car-T Cell Immunotherapy

Hematological Oncology

English

Cd19-Directed Car T Cell Therapy (Ctl019) for Relapsed/Refractory Diffuse Large B-Cell and Follicular Lymphomas: Four Year Outcomes

Hematological Oncology

English

A Window Study of Ixazomib in Untreated B-NHL

Hematological Oncology

English

Durable Responses After CD19-targeted CAR-T Cell Immunotherapy With Concurrent Ibrutinib for CLL After Prior Ibrutinib Failure

Hematological Oncology

English

Amanote Research

Discover open access scientific publications

Search, annotate, share and cite publications

Publications by Jon E. Arnason

High Durable CR Rates and Preliminary Safety Profile for JCAR017 in R/R Aggressive B-NHL (TRANSCEND NHL 001 Study): A Defined Composition CD19-Directed CAR T Cell Product With Potential for Outpatient Administration

Related publications

Safety and Preliminary Efficacy in Patients With Relapsed/Refractory Mantle Cell Lymphoma Receiving Lisocabtagene Maraleucel in Transcend NHL 001

A Phase I Trial of 19-28z Car-T Cells Post-High Dose Therapy and Autologous Transplantation (Hdt-Asct) for Relapsed and Refractory (R/R) B-Cell Non-Hodgkin Lymphoma (B-Nhl)

Novel BAFF-R CAR T-Cell Therapy for CD19 Antigen-Loss Relapsed B Cell Tumors

Phase Ib Study of Cc-122 in Combination With Obinutuzumab (Ga101): Relapsed or Refractory (R/R) Patients With B-Cell Non-Hodgkin Lymphomas (Nhl)

VENETOCLAX (VEN), BENDAMUSTINE (B) AND RITUXIMAB (R) IN PATIENTS (PTS) WITH RELAPSED OR REFRACTORY (R/R) NON-HODGKIN LYMPHOMA (NHL): FINAL RESULTS OF a PHASE I STUDY

High Rate of Durable Complete Remission in Follicular Lymphoma After Cd19 Car-T Cell Immunotherapy

Cd19-Directed Car T Cell Therapy (Ctl019) for Relapsed/Refractory Diffuse Large B-Cell and Follicular Lymphomas: Four Year Outcomes

A Window Study of Ixazomib in Untreated B-NHL

Durable Responses After CD19-targeted CAR-T Cell Immunotherapy With Concurrent Ibrutinib for CLL After Prior Ibrutinib Failure